Alle Studien
RekrutierungPHASE3INTERVENTIONELL

A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease

Fabry disease is a rare genetic condition where the body cannot properly break down a fatty substance called Gb3. Over time, this fat collects in vital organs, especially the kidneys, and can cause long-term damage. This study is testing an investigational medicine called lucerastat in adult men aged 18 to 60 with Fabry disease who are not currently on treatment. It is an open-label trial, meaning everyone who takes part will receive lucerastat rather than a dummy drug (placebo). Participants will take lucerastat daily for 18 months and be monitored over 21 months in total. Doctors will check kidney health through regular clinic visits and two kidney biopsies—one at the start and one at the end. The goal is to see if lucerastat can clear the fatty buildup from kidney cells safely.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Idorsia Pharmaceuticals Ltd.
Einschreibeziel
16
Starten
01 Dez 2026
Geschätzte Fertigstellung
15 Mar 2029

Worum geht es in dieser Studie?

Fabry disease is an inherited condition caused by a faulty gene. Because of this gene change, the body lacks an important enzyme needed to clear out a fatty substance called Gb3. Without this enzyme, Gb3 gradually builds up inside cells throughout the body, particularly in the kidneys, heart, and nervous system. Over time, this buildup can lead to organ damage, pain, and reduced kidney function.

Current treatments for Fabry disease exist in the UK, such as enzyme replacement therapy given by regular drips. However, researchers are studying lucerastat to see if an oral medicine can work differently by reducing the amount of fat the body produces in the first place. This trial focuses on whether lucerastat can reduce the amount of Gb3 stored in the kidneys of men who have not had recent treatment.

Because this is a Phase 3 study, doctors are looking closely at both how well the medicine works and whether it causes any unwanted side effects. The results could help scientists understand if lucerastat is a safe and helpful future treatment option for people living with Fabry disease.

Wichtige Erkenntnisse

  • Tests an experimental daily tablet called lucerastat for adult men with Fabry disease.
  • Open to men aged 18 to 60 who are not currently receiving Fabry treatments.
  • Everyone on the trial receives the study drug (no dummy pills are used).
  • Requires daily medication for 18 months, 10 clinic visits, and two kidney biopsies.
  • Participation is voluntary, and existing approved NHS treatments are available.

Wer könnte berechtigt sein?

This trial is for men aged between 18 and 60 who have a confirmed diagnosis of Fabry disease. To be eligible, you must have symptoms related to the condition, such as burning nerve pain, specific patterns on the surface of the eye, or small dark red spots on your skin. You must also be untreated, meaning you have not had an approved or trial treatment for Fabry disease in the past six months.

You will not be able to join if you have severe kidney problems, bleeding disorders, or other medical issues that make having a kidney biopsy unsafe. You must also have adequate blood counts and be able to safely pause any blood-thinning medicines if needed for the biopsy.

In the UK, approved treatments for Fabry disease are already available on the NHS. Before joining, doctors will discuss these existing options with you so you understand that lucerastat is still an experimental medicine undergoing testing.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am a man aged between 18 and 60.
  2. I have a confirmed diagnosis of Fabry disease.
  3. I have not received any treatment for Fabry disease in the last 6 months.
  4. I have symptoms such as nerve pain, dark skin spots, or eye changes linked to Fabry disease.
  5. I am willing and medically able to undergo two kidney biopsies.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

Taking part in this study lasts for up to 21 months. You will take lucerastat tablets every day for 18 months. During the trial, you will visit the hospital clinic about 10 times for health checks, blood tests, and urine tests to monitor your kidneys and general wellbeing.

You will also have two kidney biopsies—one near the beginning of the study and one at the end. A biopsy is a minor procedure where doctors take a tiny sample of kidney tissue using a needle, allowing them to measure the exact amount of fat inside your kidney cells. The study team will support you throughout and monitor you closely for any side effects.

Potenzielle Risiken und Vorteile

Taking part may help reduce the buildup of fat in your kidneys, but because lucerastat is an experimental medicine, there is no guarantee it will improve your health. You may also experience unknown side effects from the drug. The kidney biopsies carry minor risks such as temporary pain, bruising, or bleeding. Taking part in research is entirely voluntary; you can choose to leave the study at any time without giving a reason, and your standard NHS care will not be affected.

Standorte (16)

  • University of Alabama of Birmingham
    Verifizierte Postleitzahl
    Birmingham, Vereinigte Staaten· Noch nicht rekrutiert
  • UCSF Benioff Childens Hospital
    Verifizierte Postleitzahl
    Oakland, Vereinigte Staaten· Noch nicht rekrutiert
  • UF Health Center for Pediatric Neuromuscular and Rare Diseases
    Verifizierte Postleitzahl
    Gainesville, Vereinigte Staaten· Noch nicht rekrutiert
  • Emory University School of Medicine
    Verifizierte Postleitzahl
    Atlanta, Vereinigte Staaten· Noch nicht rekrutiert
  • Ann & Robert H. Lurie Childrens Hospital of Chicago
    Verifizierte Postleitzahl
    Chicago, Vereinigte Staaten· Noch nicht rekrutiert
  • The University of Minnesota, Fairview Health
    Verifizierte Postleitzahl
    Minneapolis, Vereinigte Staaten· Noch nicht rekrutiert
  • Hospital of University Pennsylvania, Translational Medicine and Human Genetics
    Verifizierte Postleitzahl
    Philadelphia, Vereinigte Staaten· Noch nicht rekrutiert
  • Dallas Nephrology Associates (DNA) - Dallas Landry Office Practice
    Verifizierte Postleitzahl
    Dallas, Vereinigte Staaten· Rekrutierung
  • VG Site pharmacy Dept 6 N-279
    Verifizierte Postleitzahl
    Halifax, Canada· Noch nicht rekrutiert
  • CIUSSS-NIM/Hopital du sacre-Coeur de MontrealUnite de Recherche, Local C2030
    Verifizierte Postleitzahl
    Montreal, Kanada· Noch nicht rekrutiert
  • Centre Hospitalier Universitaire de Toulouse -Hôpital Purpan
    Verifizierte Postleitzahl
    Toulouse, Frankreich· Noch nicht rekrutiert
  • Hôpital Raymond-Poincaré
    Verifizierte Postleitzahl
    Garches, France· Noch nicht rekrutiert

Häufige Fragen

Will I receive a placebo (dummy pill)?

No. This is an open-label study, which means every participant receives the active trial medicine, lucerastat.

What is a kidney biopsy?

A kidney biopsy is a common medical test where a doctor numbs the skin and uses a thin needle to remove a tiny piece of kidney tissue for examination under a microscope.

Why is this trial only open to men?

Fabry disease is linked to the X chromosome, meaning men generally have more severe enzyme deficiencies and clearer kidney fat buildup, making it easier for scientists to measure if the medicine works.

Can I leave the trial if I change my mind?

Yes. You are free to stop taking part at any point. Your normal healthcare and relationship with your doctors will continue as normal.

Does taking part cost anything?

No, the trial medicine and all tests are provided free of charge, and travel expenses to clinic visits are usually reimbursed.

Wie Sie mehr erfahren können

Clinical Trial Information USA

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study to Learn How Well Lucerastat Works and How Safe it i… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.